Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LioCyx-M Monotherapy or with Lenvatinib in Advanced HBV-related HCC
NCT05195294Phase 2Not yet recruiting
- Sponsor
- Lion TCR
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Bone Marrow HSCs, Gene Silencing
01
Overview
A Phase 2 trial of liocyx-m in hepatocellular carcinoma (HCC), sponsored by Lion TCR. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
liocyx-m
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05195294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05195294.